Autoimmune diabetes

Curing autoimmune diabetes  (TIDM) with commonly available blood pressure drug Carvedilol:  Carvedilol-based therapy for autoimmune diabetes: Carvedilol (brand name: Coreg and others),  a non-selective beta blocker used to treat high blood pressure and congestive heart failure, increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 8/June/2019, 11.22 pm
Curing autoimmune diabetes  (TIDM) with commonly available blood pressure drug Carvedilol:  Carvedilol-based therapy for autoimmune diabetes: Carvedilol (brand name: Coreg and others),  a non-selective beta blocker used to treat high blood pressure and congestive heart failure, increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 8/June/2019, 11.22 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical Sciences, University of…

read more

Combinatorial therapy for autoimmune diabetes (TIDM):  A pharmaceutical mixture encompassing Prostaglandin E2 (PGE2) and Verapamil (VM) [PGE2VM] increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up regulation of its target gene, 24/Mat/2019, 10.42 pm
Combinatorial therapy for autoimmune diabetes (TIDM):  A pharmaceutical mixture encompassing Prostaglandin E2 (PGE2) and Verapamil (VM) [PGE2VM] increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up regulation of its target gene, 24/Mat/2019, 10.42 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical Sciences, University of…

read more

PreImplantation Factor (PIF)-based therapy for autoimmune diabetes (TIDM): Synthetic preimplantation factor (sPIF) increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up regulation of its target gene, 12/April/2019, 8.31 am
PreImplantation Factor (PIF)-based therapy for autoimmune diabetes (TIDM): Synthetic preimplantation factor (sPIF) increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up regulation of its target gene, 12/April/2019, 8.31 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical Sciences, University of…

read more

Ribonucleic acid-based therapy for autoimmune diabetes (TIDM): LncRNA H19 increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up regulation of its target gene, 22/March/2019, 8.14 am
Ribonucleic acid-based therapy for autoimmune diabetes (TIDM): LncRNA H19 increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up regulation of its target gene, 22/March/2019, 8.14 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical Sciences, University of…

read more

Ribonucleic acid-based therapy for autoimmune diabetes: LncRNA MEG3 increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 21/March/2019, 8.49  am
Ribonucleic acid-based therapy for autoimmune diabetes: LncRNA MEG3 increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 21/March/2019, 8.49  am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical Sciences, University of Milan, Milan…

read more

Ribonucleic acid-based therapy for autoimmune diabetes: LncRNA MAR1 increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 20/March/2019, 12.16 pm
Ribonucleic acid-based therapy for autoimmune diabetes: LncRNA MAR1 increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 20/March/2019, 12.16 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical Sciences, University of Milan, Milan…

read more
Start Typing